Clinical Studies

Unwanted Interactions Among Psychotropic Drugs and Other Treatments for Autism Spectrum Disorders

 

A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders

 

For More Scientific Information on NeuroProtek:

- Frequently Asked Questions

- Brochure

- FDA Certificate

 

Unwanted Interactions Among Most Common Treatment Regimens in Autism

 

Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek – an oral multi-agent natural supplement

 

A Pilot Open Label Study Of Cystoprotek In Interstitial Cystitis

 


Double-blind, placebo-controlled, cross-over study for the treatment of remitting-relapsing multiple sclerosis.  (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: S.L. Hauser, M.D. Site: Massachusetts General Hospital, Boston, MA).

 

Double-blind, placebo-controlled, study for the treatment of interstitial cystitis.  (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: G.R. Sant, M.D. Site: Clinical Research Center, New England Med. Center).

 

Double-blind, placebo-controlled, study for the prevention of migraine headaches. (Principal Investigator: T.C. Theoharides, Ph.D., M.D; co-PI: E. Spierings, M.D., Ph.D.  Site: Boston, Clinical Research Center, Newton, MA-2004).

 

Single-blind, open label study of the effect of a flavonoid formulation on niacin-induced flush. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Dimitris Kalogeromitros, Ph.D., M.D. Site: Attikon Hospital, Athens, Greece-2008).

 

Single-blind, open label study of the effect of a flavonoid formulation, CystoProtek, on interstitial cystitis. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Grannum R. Sant, M.D. Site: Multiple throughout the USA-2008).

 

Single-blind, open label study of the effect of a flavonoid formulation on niacin-induced flush. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-I: Dimitris Kalogeromitros, Ph.D., M.D. Site: Attikon General Hospital, Athens, Greece-2009).

 

Open label study of biomarkers in young children with autism. (Principal Investigator: T.C. Theoharides, Ph.D., M.D., Co-Is: Dimitris Kalogeromitros, Ph.D., M.D., Konstantinos Francis, M.D. Site: Attikon General Hospital, Athens, Greece-2009).

 

Open label study of tolerability and effectiveness of NeuroProtekÒ in autistic children (Principal Investigator: Prof. L. Lykouras . site: Second Department of Psychiatry, Attikon Hospital Athens, Greece-2011)

 

Double-blind, placebo-controlled, cross-over study of a flavonoid formulation for the treatment of autism.  (Principal Investigator: T.C. Theoharides, Ph.D., M.D, Co-PI: Isaac Melamed, M.D. Site:IMMUNOe, Centennial, CO).

 

 

Questions & Answers

Q: There are references in Dr Theo's work to Neuroprotek being a liposomal formulation with the olive kernel oil. My understanding of liposomal formulations such as the various lipo-C and lipo-glutathione supplements on the market is that means encasing the particles in tiny spheres of phospholipids. Obviously, olive kernel oil is not a phospholipid. Is there something I'm missing? Or is calling neuroprotek a liposomal formulation just a "loose" description? See for instance, the wikipedia page on liposomes: http://en.wikipedia.org/wiki/Liposome. I wonder what Dr Theo's take is?

 

A: Olive kernel oil contains many lipids, including phospholipids. Any time you add energy to an oil it assumes the least energy configuration which is a sphere. The more energy you provide, the smaller the microspheres. During this process, the microspheres encapsulate the solutes, in this case the flavonoids. NeuroProtex is prepared by mixing the ingredients with olive kernel oil using a proprietary procedure. Even though the word liposome was originally coined to mean use of synthetic phospholipids, it is used for any type of liposomamal preparation. If the term microsphere is preferable for the public, we can use this instead.

 

 

upcoming events
16September

Nashville Support Group Meeting - Saturday, September 16, 2017
10a-4p Hermitage Library, 3700 James Kay Lane, Hermitage, TN 37076
Speaker: Dr. Theoharides, MD

 

 

21October

Brain Fires in Autism: Mast Cells, Microglia and Brain Inflammation
Hilton Orange County Hotel in Costa Mesa, BELIEVE room 2 – 8:00AM

 

 

22October

Stress, Brain Inflammation and Brain Fog in Autism
Hilton Orange County Hotel in Costa Mesa, BELIEVE room 2 – 8:00AM

 

 

11November

Bari (Italy), 2nd European Conference of Biomedical Research and Treatments of Autism - Mast cell-microglia connection leading to focal inflammation of the brain in autism
Saturday @ 15.40
Brochure (PDF)

 

 

30November

Queen Mary University of London,
15:30-15:30-Regulatory systems pathway from stress to disease and possible parallels to periodontal disease
Email: a.b.o.gamboa@qmul.ac.uk

 

 

30November

Queen Mary University of London,
15:30-16:00-Interventions on the immune regulatory systems
Email: a.b.o.gamboa@qmul.ac.uk

 

 

01December
02December

Conway Hall, London, 10:00 am,
Role of Mast Cells in Inflammatory Diseases

 

 

Prof. Theoharides' Invited Lectures (2015-16)

  • • Australia Autism Lecture (April 24, 2015; Melbourne, Australia)
  • • Boston Conservatory of Music (May 5, 2015; Boston, MA)
  • • Autism Education Summit (September 26, 2015; Dallas, TX)
  • • National Autism Association (October 15, 2015; St. Pete, FL)
  • • Autism Research Institute (December 5, 2015; Boston, MA, 2015)
  • • Cyprus Pediatric Association (February 14, 2016; Nicosia, CY)
  • • TARF Think Tank (February 19, 2016; Boston, MA)
  • • NCIMS (February 27, 2016;Greenboro, NC)
  • • TACA Massachusetts (March 12, 2016; Watertown MA)
  • • 11th PanHellenic Conference on Allergy & Clinical Immunology (April 16, 2016; Athens, Greece)
  • • TACA Webinar (April 25, 2016; 1 pm)
  • • All Childrens Hospital (April 1, 2016; St. Pete, FL)
  • • TACA Philadelphia (May 7, 2016; Philadelphia, PA)
  • • Autism One (May 27, 2016; Chicago, IL)
  • • Autism One Think Tank (May 28, 2016; Chicago, IL)
  • • EAAACI (June 7-11, 2017; Vienna, Austria)
  • • Old North State Medical Society (June 23-25, 2016; Raleigh, NC)
  • • FASEB Summer Research Conference in the long-running Neuroimmunology series entitled "Translational Neuroimmunology: From Mechanisms to Therapeutics" (July 24-29, 2016; Big Sky, MT)
  • • 11th Annual USAAA World Autism and Asperger Conference (August 29, 2016; Louisville, KY)
  • • MAPS Conference (September 9, 2016; Atlanta, GA)
  • • The Mastocytosis Society (September 15-17, 2016; Orlando, FL)
  • • International College of Geriatric Psychoneuropharmacology (ICGP) (October 7, 2016; Athens, Greece)
  • • TACA National Conference (October 22, 2016; Costa Mesa, CA)
  • • ILADS Annual meeting (November 4, 2016; Philadelphia, PA)
  • • 37th UMEMPS (Union of Middle-Eastern and Mediterranean Pediatric Societies-Cyprus Pediatric Society (November 6, 2016; Limassol, Cyprus)
  • • 1st International Conference on Autism (November 22, 2016; Paphos, Cyprus)

EAAACI=European Academy of Allergy and Clinical Immunology
ILADS=International Lyme and Associated Diseases Society
MAPS=Medical Academy of Pediatrics  Se-0pcial Needs
NCIMS=North Carolina Integrative Medical Society
TARF=The Autism Research Foundation
TACA=Think About Curing Autism
ILADS=International Lyme and Associated Diseases Society


 

 

Neuroprotek® is available at the following sites:

Algonot
Where Science and Natural Remedies Meet®

 

NAA

 

Spectrum Supplements
Canada

 

Mandi Mart
UK

 

 

Quick contact